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Summary The in vitro and in vivo stability and anti-tumour efficacy of the anti-EGFR/anti-CD3 bispecific
monoclonal antibody (biMAb), M26.1, were analysed. The interaction of the intact biMAb with Fc receptor I
(Fc'yRI) present on human leucocytes was not observed when the antibody was used as an F(ab')2 fragment. A
CD8+ T-cell clone coated with M26.1 F(ab')2 was as effective as the intact biMAb in inducing IGROVI target cell lysis when tested in a 5'Cr-release assay. Variable levels of reduction of F(ab')2 to monovalent F(ab') were
observed upon incubation with human ovarian cancer ascitic fluid (OCAF) or with human glioblastoma cavity fluid (GCF), but not with mouse or human sera. Activated lymphocytes coated with F(ab')2 and incubated in
vitro with GCF or OCAF for 24 and 48 h respectively maintained their targeting. Thus, the F(ab')2, when
present as a soluble molecule, but not when bound to T cells, might lose some functional activity as a
consequence ofpartial reduction to F(ab'). In normal mice, M26. I F(ab')2 retained full cytotoxic activity in the
circulation, and clearance values were similar to those obtained with parental and other MAb F(ab')2.
Treatment of IGROVI tumour-bearing mice with activated human lymphocytes coated with the M26.1 F(ab')2
significantly prolonged survival of the animals compared with tumour-bearing untreated and control mice
treated with lymphocytes or F(ab')2 alone. Together, these results suggest the clinical usefulness of bispecific
M26.1 F(ab')2 as a targeting agent for local treatment of tumours such as glioma and ovarian cancers that
express variable levels of epidermal growth factor receptor (EGFR).
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The epidermal growth factor receptor (EGFR), a 170 kDa
transmembrane glycoprotein with tyrosine kinase activity, is
overexpressed in a wide range of human malignancies (Gul-
lick, 1991). Increased EGFR expression correlates with a
poor clinical outcome in patients with cancer of the lung,
bladder, oesophagus, breast, cervix and ovary (Hendler et al.,
1989; Fox et al., 1994). Only in glial and head and neck
tumours has EGFR over-expression been frequently
associated with amplification of the gene (Libermann et al.,
1985; Chaffanet et al., 1992; Wong et al., 1992), and on
tumour cells expression levels can be increased by several
orders of magnitude, suggesting the feasibility of therapeutic
strategies that exploit the differential levels of EGFR expres-
sion on tumours vs normal cells. Like other growth factor
receptors on tumour cells, EGFR may represent a suitable
target molecule for antibody-driven therapy. A panel of anti-
EGFR monoclonal antibodies (MAbs) is now available (Gill
et al., 1984; Rodeck et al., 1987; Mendelsohn 1990) and
several of them have been applied in preclinical (Bender et
al., 1992; Baselga et al., 1993; Fan et al., 1993a,b) and clinical
immunotherapeutic settings (Kalofonos et al., 1989; Divgi et
al., 1991; Brady et al., 1992).
MAbs specific for tumour-associated antigens (TAAs) have
been used to construct bispecific reagents in conjunction with
MAbs against T-lymphocyte surface molecules capable of cell
activation, such as the CD3/TCR complex (Segal et al., 1988;
Beun et al., 1994). These biMAbs can target T-cell-mediated
cytotoxicity and induce lysis of target cells in an MHC-
independent manner. BiMAbs have been employed to arm
large numbers of effector cells in vitro (Pupa et al., 1988),
which have been used to control tumour cell growth in nude
mice bearing human cancer xenografts (Mezzanzanica et al.,
1991a; Renner et al., 1994) and also in humans with ovarian
(Bolhuis et al., 1992) and brain tumours (Nitta et al., 1990).
We previously described an anti-EGFR/anti-CD3 biMAb,
termed M26.1, that specifically targets activated T lym-
phocytes, but not resting peripheral blood lymphocytes
(PBLs), against EGFR+ tumour cells (Ferrini et al., 1993).
When low concentrations of biMAb were present, only
tumour cells with a moderate to high level of EGFR were
lysed, indicating that induction of tumour cell lysis was
strictly dependent upon the level of the expression of the
EGFR molecule on target cells (Ferrini et al., 1993).
In the present preclinical analysis we show that the M26.1
biMAb F(ab')2 retains its ability to trigger T-cell activity
against specific target cells either, as a soluble molecule, after
recirculation in normal mice or, bound to T cells, after in
vitro incubation in the presence of human pathological fluids.
More importantly, we demonstrate the efficacy of biMAb-
armed T lymphocytes in prolonging survival of tumour-
bearing mice in an ovarian cancer xenograft immunotherapy
model. These results strongly suggest the suitability of anti-
EGFR/anti-CD3 biMAb F(ab')2-coated T lymphocytes for
the local treatment of EGFR-expressing tumours.
Materials and methods
Cell lines
K562 human leukaemia and U937 human lymphoma cells
were from ATCC (Rockville, MD, USA). IGROVI human
ovarian carcinoma cells were kindly provided by J Benard
(Institute Gustave Roussy, Villejuif, France). All cell lines
were grown in RPMI-1640 medium supplemented with 10%
fetal calf serum (FCS), 2 mM glutamine and streptomycin
(100 ,Lm ml-') in a humidified atmosphere of 5% carbon
dioxide at 37°C. Cells were routinely tested for mycoplasma
contamination using the Hybricomb Mycoplasma test kit
(Biological Industries, Israel) and were consistently negative.
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M26.1 biMAb (IgGl/IgG2a) was produced by fusion of an
anti-EGFR hybridoma (IgGI) derived from mice immunised
with EGFR-overexpressing A431 cells together with an anti-
CD3 hybridoma (IgG2a), derived from mice immunised with
human T lymphoblasts and which recognizes human but not
murine CD3 (Ferrini et al., 1993). The two parental MAbs
and the hybrid biMAb were purified from mouse ascitic fluid
by chromatography on a Sepharose-protein A column using
a three-step pH elution gradient of 0.1 M sodium citrate.
Purified bispecific M26.1 was analysed as described
previously (Ferrini et al., 1993) by hydroxyapatite high-
performance liquid chromatography (HPLC) using a linear
gradient (10-350 mM) of potassium phosphate, pH 6.8.
MAbs 197 and 3G8-FITC (Medarex) and CD32 FcR2
(Amac), which specifically detect respectively Fc'yRI, Fc-yRIII
and Fc'yRII, were used to monitor expression of the relevant
target molecules.
Biologicalfluids
Human sera from healthy donors were collected and pooled;
human ascitic fluids (OCAFs) were derived from advanced
ovarian cancer patients; glioblastoma cavity fluids (GCFs)
were recovered from the cystic cavity remaining after tumour
excision from glioblastoma patients. All biological fluid sam-
ples were centrifuged and filtered through 0.22 ym filters, and
stored at - 20C until assayed. Protein concentrations were
calculated using the Pierce BCA protein assay. A transform-
ing growth factor beta-l (TGF-P1) enzyme-linked immuno-
sorbent assay (ELISA) kit (Genzyme) was used to determine
the presence of TGF-P in GCF and OCAF.
Immunofluorescence assay
Tumour cell lines were analysed for reactivity with MAbs by
FACScan analysis. Approximately 4 x 105 cells were
incubated for 30 min at 0°C with 0.1 ml of reagent (anti-
EGFR, anti-CD3, M26.1 or anti-FcyRs) at a concentration
of 10pgml-'. The anti-Fc'R reagents were mixed with
human 'y-globulins (Sigma) at 2 mg ml-' to block Fc region-
specific binding of MAb.
Preparation ofbivalent MAbfragments
F(ab')2 fragments of M26.1 biMAb and anti-CD3 MAb were
obtained by pepsin digestion. MAb or biMAb were dialysed
overnight against 20 mm sodium acetate buffer (pH 4.2), fol-
lowed by digestion with 4% (w/w) pepsin for 6 h at 37°C.
Digestion was terminated by addition of Tris-HCI buffer
(pH 9.2), and pepsin and fragments were removed by over-
night dialysis (molecular wt cut-off, 50000) against 10 mM
sodium phosphate buffer (pH 8.2) containing 150 mM sodium
chloride. Undigested MAbs were separated from F(ab')2
fragments on an ImmunoPure Plus-immobilised protein A
gel (Pierce, Rockford, IL, USA) using the ImmunoPure IgG
purification buffers. Purity of the fragment was analysed by
4-15% SDS-PAGE in a precast slab gel (Pharmacia
Biotechnology, Uppsala, Sweden), using the automated
microprocessor driven Phastsystem (Pharmacia) according to
the manufacturer's suggestions. The F(ab')2 fragment of anti-
EGFR MAb was obtained by ficin digestion as described
(Mariani et al., 1991).
Pharmacokinetics studies
Pathogen-free female athymic mice (nu/nu CD1 background)
or normal BALB/C mice, 6-8 weeks old, were obtained from
Charles River (Calco, Como, Italy). Mice were held for 1-2
weeks before initiating experiments. Animals were housed
under sterile conditions and received autoclaved food and
water. According to their sensitivity to labelling procedures,
M26.1 and its F(ab')2 were labelled with 1251I using lodogen,
whereas anti-EGFR and its F(ab')2 were labelled using the
Anti-EGFR/Anti-CD3 F(ab')2 biMAbstability and efficacy
DRM Negri etal
929
lactoperoxidase method (Marchalonis, 1969). Mice were
injected i.p. with 1.8-3.4 ig of 251I-labelled intact MAb or
F(ab')2 (sp. act. 2.7-5.2ILCi sg-') or with 10 lAg of unlabelled
F(ab')2 M26.1. Blood samples were collected at various times
(from 30min to 72h) after administration (three mice for
each time point) and serum was recovered. For mice injected
with radiolabelled reagents, an aliquot of each serum sample
was counted in a gamma-counter and protein-bound radioac-
tivity was measured by paper chromatography in 10% trich-
loroacetic acid. For mice injected with unlabelled reagent, the
presence of active F(ab')2 in blood serum samples were
evaluated in a standard 4 h 51Cr-release assay. Phar-
macokinetic parameters were calculated using the
MKMODEL modelling program (Biosoft, Cambridge, UK).
Activation and coating ofhuman PBL
Freshly obtained PBLs from healthy donors were activated,
expanded and coated with M26.1 biMAb F(ab')2 as described
(Bolhuis et al., 1992).
Cytotoxicity assays
Activated lymphocytes, T-cell polyclonal lines and T-cell
clones (Ferrini et al., 1989) were used as effector cells and
IGROVI cells were used as target at effector-target cell
ratios from 10:1 to 40:1 in a 4h 51Cr-release assay. For
analysis of MAb-induced cytotoxicity, various concentrations
of biMAb or F(ab')2 were added at the start of the assay. To
test whether biMAbs maintained their ability to trigger
cytolysis, coated lymphocytes were incubated in vitro for
different times in the presence of OCAF or GCF (final
dilution, 1:2). Unwashed lymphocytes were added at a given
time to labelled target cells at an effector-to-target cell ratio
of 40:1 and specific lysis was assayed in a 4 h 5'Cr-release
assay. Per cent lysis and biMAb or F(ab')2 concentrations
producing half-maximal cytolysis (ED50) were evaluated as
described.
Stability ofF(ab')2 biMAb
An aliquot of 5IlI of 1251I-labelled F(ab')2 biMAb was
incubated at 37°C with 45pl of BALB/C mouse or human
sera, OCAF and GCF samples, or saline. At various times
from 30 min to 72 h, 1 IlI (2000 c.p.m.) of each sample was
analysed by 4-15% SDS-PAGE, autoradiography for a
week at - 80°C and densitometry.
In vivo activity ofF(ab')2 biMAb
Five groups of athymic mice (8-12 animals per group, see
Table III) were injected i.p. with 107 IGROVI cells, main-
tained in vivo by serial transplants, on day 0. Animals were
injected i.p., twice a day, on days +3 and +4 with various
combinations of activated PBLs and parental MAbs or
biMAb. Mice were monitored for abdominal swelling and
mortality. Treatment effects were compared by Wilcoxon and
log-rank non-parametric tests.
Results
BiMAb FcR interaction
We previously described a heteroisotypic (IgGl/IgG2a) anti-
EGFR/anti-CD3 biMAb M26.1, secreted by a hybrid hybrid-
oma (Ferrini et al., 1993). This antibody was unable to
mediate antibody-dependent cell-mediated cytotoxicity
(ADCC) by CD16+ (Fc-yRIII+) natural killer (NK) cells. To
determine whether the Fc region of this biMAb interacted
with Fc-yRI and/or II, the binding of M26.1 and the parental
anti-EGFR and anti-CD3 MAbs was evaluated by
immunofluorescence and FACS analysis. Figure 1 shows the
binding of control anti-Fc-yR MAbs (a) and of the relevantAnt-EGFR/Anfi-CD3 F(ab)2 biMAb stability and efficacy
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MAbs (b) to the two FcyR-positive cell lines U937 and K562
and to the EGFR-positive line IGROVI (4 x 104 EGF bin-
ding sites per cell). As shown in Figure la, both anti-FcyRI
and anti-FcyRII bound to U937 cells, only anti-FcyRII
reacted with K562 cells and none of the anti-FcyR MAbs
reacted with IGROVI cells. The intact anti-EGFR MAb and
biMAb molecules bound to EGFR-positive, FcyRI- and II-
negative IGROVI cells and to EGFR-negative, Fcy?RI- and
II-positive U937 cells, while intact anti-CD3 interacted only
with U937 cells. BiMAb failed to bind with FcyRI-negative
FcyRII-positive K562 cells. Binding with U937, but not with
IGROVI cells, was abolished by preincubation of cells with
human IgG (data not shown) or by removal of MAb Fc
portion (Figure 1). These results indicate that intact MAbs
and biMAb can bind to FcyRI present on human cells.
Therefore, to avoid unwanted interactions of biMAb with
FcyRI in vivo, the F(ab')2 fragment of the biMAb was
generated and used for further experiments.
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Figure 1 Flow cytometric analysis of MAb reactivity with
IGROVI, U937 and K562 tumour cell lines. (a) Binding reac-
tivity of anti-FcyR MAbs: 1, control; I, anti-FcyRI; II, anti-
FcyII; III, anti-FcyRIII. (b) Binding reactivity of anti-EGFR,
anti-CD3 MAbs or F(ab')2 fragments: 1, control; 2, anti-EGFR;
3, anti-EGFR F(ab')2; 4, anti-CD3; 5, anti-CD3 F(ab')2; 6,
M26.1; 7, M26.1 F(ab')2.
In vitro activity and stability ofbiMAb F(ab')2
Comparison of the ability of the F(ab')2 vs intact biMAb to
target a CD8+ T-cell clone against IGROVI cells in a "Cr-
release assay revealed that the F(ab')2 biMAb was as effective
as the intact biMAb (ED50 = 5.3 and 4.9 ng ml-' respec-
tively) in inducing target cell lysis. Analysis of the biological
activity of the F(ab')2 fragment in the presence of normal
mouse sera indicated that the concentration of reagent
required to induced half-maximal cytolysis was comparable
to that required in standard culture medium (data not
shown). To further analyse F(ab')2 biMAb stability in
different biological fluids, labelled F(ab')2 was incubated in
vitro in the presence of normal mouse and human sera, four
different OCAFs or four GCFs and the samples were
analysed at various time intervals by SDS-PAGE followed
by densitometry (Table I). In OCAFs, but not in mouse and
human sera, there was a slight reduction of intact F(ab')2
biMAb, indicated by the appearance of a band correspon-
ding to F(ab') (50 000 kDa) detected at 72 h. In GCFs,
variable levels of reduction to F(ab') were evident at 24h
(5-23%), increasing up to 53% by 48 h after incubation with
GCFs 1 and 4. The difference in reducing capacity did not
depend on protein concentration. The large variability might
be due to differences in reducing agents in the different
samples. Indeed despite a wide variability among patients,
reproducible results were obtained when individual samples
were analysed in repeated tests (data not shown). However
the biMAb F(ab')2, when bound to T cells, was remarkably
stable during prolonged in vitro incubation with different
pathological fluids. Human activated T lymphocytes coated
with M26.1 F(ab')2 and incubated in vitro in the presence of
GCFs or OCAFs for 24 h and 48 h respectively, maintained
their ability to lyse IGROVI target cells in a 5"Cr-release
assay (Figure 2). The presence of the immunosuppressive
cytokine TGF-01, which was detected in variable amounts in
GCF and OCAF, did not seem to influence the cytotoxic
ability of activated lymphocytes.
Pharmacokinetics
To test whether the biMAb F(ab')2 fragment retained its
targeting activity in vivo BALB/C mice were injected with the
reagent and serum samples obtained at different time inter-
vals were tested for their ability to trigger cytolytic T lym-
phocytes in a 51Cr-release assay against IGROVI target cells
(Figure 3). At 2 and 6h after injection, the dilutions of
mouse sera able to induce lysis were superimposable. F(ab')2
biMAb activity progressively decreased after 24h but was
still detectable at 72 h. The pharmacokinetic and the half-life
values (t,/2p) calculated on the basis of this functional assay
were similar to those of radiolabelled F(ab')2 evaluated in
conventional pharmacokinetics assay (Table II). The same
labelled reagent had a shorter t1/2P (approximately 7 h) in
athymic mice, suggesting a different pharmacokinetic
behaviour in the two mouse strains, as already reported by
Table I Densitometric analysis of M26.1 biMAb and anti-EGFR F(ab')2 fragments after incubation with different biological
fluids
24h 48h 72h
Sample Sample code mgml-a anti-EGFR biMAb anti-EGFR biMAb anti-EFGR biMAb
Saline, mouse and - - - - - -
human sera
OCAF A 17.8 - - - 6.3 6 11.8
B 26.1 - - - 8.2 6 18.8
C 31 - - - 12.4 6 12.7
D 31.1 - - - - 6 14.5
GCF 1 2.1 ND 22.5 ND 53 ND ND
2 13.7 - 5.3 - 6.9 - ND
3 29.8 - 12.9 20.9 36.8 28.6 43.4
4 1.2 - 23.2 25 51.3 26.3 ND
Data are expressed as relative percentage of monovalent F(ab'). aProteic concentration. OCAF, Ovarian cancer ascitic fluid;
GCF, glioblastoma cavity fluid; -, not detectable; ND, not done.
930others (Sharkey et al., 1991). The shorter t1/2P of M26.1
F(ab')2 as compared to parental anti-EGFR F(ab')2 might
reflect a more rapid degradation of the heteroisotypic form.
When biMAb and parental anti-EGFR MAb were com-
pared, similar values were obtained.
In vivo anti-tumour activity ofhuman T cells targeted by
biMAb F(ab')2
The in vivo anti-tumour activity of PBLs targeted by biMAb
F(ab')2 was evaluated in a preclinical model of human
tumour xenografts in nude mice. Intraperitoneal injection of
107 IGROVI cells into the mice caused death rapidly, with a
mean survival time of 10.75 days (Table III). Tumours
developed as large volumes of ascites accompanied by
nodules in the pancreas and mesenteric lymph nodes and in
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the diaphragm and liver. Nude mice bearing 3 day i.p.
IGROVI tumours and treated i.p. on day 3 and 4 with PBLs
alone, PBLs plus parental MAbs or M26.1 F(ab')2 alone
showed no increase in mean survival time (10.91 *. 11.83
days) as compared to untreated mice (10.75 ± 0.41 days),
whereas mice treated with activated PBLs coated with M26.1
F(ab')2 showed a significant increase in mean survival time
(23.17 ± 2.67 days, P = 0.003) (Table III, Figure 4).
Discussion
In this report, we show that the anti-EGFR/anti-CD3
biMAb M26.1, following removal of the Fc region, retains its
ability to target human T lymphocytes against EGFR+
tumours in vitro in the presence of different mouse and
human biological fluids, and in vivo in a xenotransplanted
mouse model.
Other biMAbs have been shown to interact with the three
types of IgG FcRs involved in ADCC (Fanger et al., 1989;
Mezzanzanica et al., 1991b), and with anti-TAA/anti-CD3
biMAbs, the binding with human cells via FcyR might
induce unwanted phenomena such as damage of biMAb-
coated T cells by FcyR' effectors or killing of FcyR+ targets
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Figure 2 Effect of pathological fluids (final dilution 1:2) on the
lytic activity of activated lymphocytes coated with M26.1 F(ab')2
and incubated for 24 h with four different GCFs (1,2,3,4), 48 h
with four different OCAFs (A,B,C.D) or with medium (CTR+).
Effector-target cell ratio, 40:1. The TGF-P concentration of the
undiluted fluids is given. ND, not done.
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Figure 3 Effect of different dilutions of sera from BALB/C mice
injected with biMAb F(ab')2 on the cytolytic activity of a
cytotoxic CD8+ T clone against IGROVI cells. Each value
represents the mean ± s.e. (vertical bars) of three animals. Data
are expressed as percentage of specific lysis in a 5'Cr-release assay
at an effector-target cell ratio of 20:1. (O) 2h, (0) 6h, (A)
24 h, (V) 72 h, CTR+, medium, CTR-, no biMAb.
Table II Pharmacokinetics of anti-EGFR, M26.1 and their F(ab')2
fragments in BALB/C and athymic mice
Mouse Injected Sp. act. t112p
strain dose (rig) (sCiAg-') (h)
M26.1 F(ab')2 BALB/C 10.0a - 15.4
BALB/C 3.4 3.4 15.0
Nude-CD1 1.8 4.8 7.0
Anti-EGFR F(ab')2 Nude-CD1 2.0 4.7 10.0
M26.1 Nude-CD1 2.3 2.7 152.0
Anti-EGFR Nude-CD1 2.3 5.2 144.0
aUnlabelled. Sp. act., specific activity.
Table III Treatment and survival time of IGROV1 tumour-bearing athymic mice
Treatment groups Total dose per mouse Mean survival time
(no. of mice) (biMAb and lymphocytes) ±s.e. (days) P-valuea
Control (8) 10.75 ± 0.41
F(ab')2 M26.1 (11) 80 sg 10.91 ± 0.64 NS
PBL (9) 80 x 106 11.11 ± 0.54 NS
PBL + parental F(ab')2 (12) 80fig + 80 x 106 11.83 ± 0.40 NS
PBL + F(ab')2 M26.1 (12) 80jig + 80 x 106 23.17 ± 2.67 0.003
aEvaluated by Wilcoxon test. NS, not significant.
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Figure 4 Survival curves of IGROVI tumour-bearing mice.
Mice were injected i.p. with tumour cells on day 0 and were
treated on days +3 and +4 twice a day with: physiological
solution; (0), PBLs alone (A), biMAb F(ab')2 alone (+), PBL-
+ parental F(ab')2 (0) or PBLs coated with biMAb F(ab')2 (X).
(For doses see Table III).
(Segal et al., 1988; Fanger et al., 1992). We have previously
shown that intact IgGl/IgG2a heteroisotypic biMAb does
not interact with FcyRIII present on human NK cells, being
unable to mediate ADCC by CD16+ NK cells (Ferrini et al.,
1993). In our present report, we evaluated M26.1 Fc binding
with FcyRI and II, which are expressed on different cells
such as monocytes, polymorphonuclear cells, B lymphocytes
and also microglial (murine) cells (Bender et al., 1992) and
observed that it interacted with FcTRI+ cells. Use of F(ab')2
fragments prevents this interaction, which assumes impor-
tance since one possible clinical application of this biMAb is
local treatment of human glioma.
In view of its heteroisotypic nature (IgGl/IgG2a), we
investigated the in vitro and in vivo stability of M26.1 F(ab')2
fragments. As previously reported, the pepsin cleavage site
for IgGl and IgG2a is localised in different regions, i.e. the
reaction produces a smaller segment in IgGl than in IgG2a
(Parham, 1983). Consequently, F(ab')2 of the heteroisotypic
biMAb is formed by two fragments of different length which
might lead to an increased susceptibility to proteolytic or
reducing activities. Indeed, our analysis of the stability of the
biMAb F(ab')2 vs the parental anti-EGFR fragment in the
presence of mouse and human sera or pathological human
fluids revealed a variable level of reduction of intact F(ab')2
to monovalent F(ab') after incubation with pathological
fluids, particularly in the case of GCFs. As expected, the
phenomenon was more evident with biMAb F(ab')2. How-
ever F(ab')2 biMAb-coated lymphocytes maintained the
ability to lyse EGFR+ targets even after 24 h and 48 h of
incubation with GCFs and OCAFs respectively. Thus, it
appears that biMAb F(ab')2, when present as a soluble
molecule in some biological fluids, but not when bound to T
cells, can lose functional activity as a consequence of partial
reduction.
GCF and ascitic fluids have been shown to contain
immunosuppressive factors, such as TGF-P (Hirte and Clark,
1991), which can inhibit in vitro activation and proliferation
of lytic effector cells (Wahl et al., 1989) as well as anti-
tumour cytotoxicity of cultured lymphokine activated killer
(LAK) cells (Ruffini et al., 1993). Variable levels of TGF-P
were found in all of our tested fluids, but its effect on the
biMAb-directed lytic activity of activated lymphocytes
appeared to be minimal, although the same fluids were able
to inhibit the lymphocyte activation phase (data not shown).
Further confirmation of the stability of the reagent in vivo
came from analysis in normal mice injected with M26.1
F(ab')2, where it retained full T-cell targeting activity in the
circulation, and clearance values were comparable to those
obtained with parental and other MAb F(ab')2 fragments
(Fan et al., 1993b; Van Dijk et al., 1991).
To verify the in vivo anti-tumour activity of our reagent,
we chose a preclinical survival model of nude mice using the
EGFR+ human ovarian carcinoma cell line IGROVI. This
model was selected because the tumour remains localised to
the peritoneum and can therefore be treated with local
immunotherapy. Specific in vivo targeting therapy using in
vitro-activated lymphocytes coupled with biMAb has been
described (Nitta et al., 1990; Bolhuis et al., 1992), and other
clinical trials with different biMAbs are currently underway.
Consistent with data from preclinical and clinical studies, we
find that mice treated with activated human PBLs coated
with M26.1 F(ab')2 survive significantly longer, although the
treatment did not completely eradicate the implanted
tumour. This failure probably reflects the high growth rate of
the xenograft model which causes death more rapidly (mean
survival time = 10.75 days) than in other preclinical models
(Mezzanzanica et al., 1991a; Renner et al., 1994). More
aggressive treatment might further improve survival rates and
eventually lead to tumour cure.
This biMAb retargeting approach offers several advantages
over others that utilise anti-EGFR MAbs therapeutically.
Targeting ofT cells by biMAb should allow a local release of
inhibitory cytokines at the tumour site (Qian et al., 1991)
which might act on all cells within a tumour, including cells
that were sterically inaccessible to targeted PBLs or that had
lost antigen expression. In our experimental model, adverse
effects on normal tissues would not be expected in mice
because the biMAb does not bind to the mouse EGFR
(Valota et al., submitted) and to murine CD3 (Ferrini et al.,
1993). Since human epithelia express moderate/low EGFR
levels (Rodriguez et al., 1991; Banks-Schlegel et al., 1986) the
systemic use of anti-EGFR MAbs in humans must be con-
sidered with caution. However, bispecific M26.1 F(ab')2
might be used as a targeting agent for local treatment of
tumours such as gliomas or ovarian cancers that express
variable levels of EGFR molecules, but whose surrounding
accessible normal tissues are EGFR negative.
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